NATIMMUNE A/S
NatImmune A/S operates a biotech company focusing on the development of protein-based therapeutics.
Similar Organizations
Actigen Ltd
Actigen Ltd is an biotechnology company engaged in the development of human antibody therapeutics.
Baliopharm
Baliopharm AG is a biotechnology company focusing on the development of novel therapeutics.
More informations about "NatImmune A/S"
NatImmune A/S - Crunchbase Company Profile & Funding
NatImmune A/S operates a biotech company focusing on the development of protein-based therapeutics.See details»
NatImmune Company Profile 2024: Valuation, Investors
NatImmune is headquartered in Copenhagen, Denmark. What is the size of NatImmune? NatImmune has 5 total employees. What industry is NatImmune in? NatImmune’s primary …See details»
NatImmune A/S - LinkedIn
NatImmune A/S Biotechnology Research Follow Report this company About us Industry Biotechnology Research Company size 11-50 employees Type Privately Held Locations …See details»
NatImmune A/S - VentureRadar
Find out more about NatImmune A/S including the VentureRadar Innovation and Growth scores, Similar Companies and more.See details»
NatImmune - Products, Competitors, Financials, Employees, …
NatImmune A/S has developed a product for replacement therapy of Mannan Binding Lectin (MBL) in patients carrying genetic pre-disposition to infections through a deficiency in the …See details»
NatImmune - Company Profile - Tracxn
Sep 15, 2024 · NatImmune - Developer of protein therapeutics for oncology and infectious diseases. Raised funding from 1 investor. NatImmune has 3071 competitors.See details»
NatImmune A/S - Crunchbase
NatImmune A/S operates a biotech company focusing on the development of protein-based therapeutics.See details»
NatImmune A/S - life-sciences-europe.com
Oct 1, 2005 · BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl – the European Association of Bioindustries; BioIndustry …See details»
Natimmune - Overview, News & Competitors | ZoomInfo.com
NatImmune is a Medicon Valley based biopharmaceutical company, which was founded in 2000 to develop best-in-class protein therapeutics within oncology and infectious diseases. In 2005, …See details»
NatImmune A/S - BioCentury Company Profiles - BCIQ
Feb 16, 2009 · NatImmune A/S - BioCentury Company Profiles for the biopharma industrySee details»
NatImmune A/S - M&A Summary and Business Overview - Mergr
NatImmune A/S M&A Summary. NatImmune A/S has acquired 1 company. The Company’s most targeted sectors include medical products (100%). NatImmune A/S Business OverviewSee details»
Alan Ezekowitz Ph.D Profile: Contact Information & Network
Alan Ezekowitz Ph.D holds 5 board seats including Corner Therapeutics, Fulcrum Therapeutics, NatImmune, Organon & Co., and Septerna. Discover how our experts ensure you’re getting …See details»
BAMLET(NatImmune A/S) - Drug Targets, Indications, Patents
BAMLET (NatImmune A/S), Initially developed by Azanta Danmark A/S, Now, its global highest R&D status is Pending, Therapeutic Areas: Neoplasms,Urogenital Diseases.See details»
NatImmune, Enzon Enter Deal On Recombinant MBL - BioWorld
Oct 5, 2005 · NatImmune A/S licensed its lead project, recombinant human mannan-binding lectin (rhMBL), in development for prevention of severe infection in MBL-deficient individuals …See details»
Martin Bonde - CEO @ Inthera Bioscience - Crunchbase
Torsana Biosensor AS (CEO), Celtor Biosystems Inc (EVP), Combio AS (CEO), Natimmune AS (CEO), Aros Pharma ApS (CEO) and most recently Epitherapeutics Aps now sold to Gilead …See details»
NatImmune Management Team - CB Insights
Explore {NatImmune's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»
NatImmune Stock Price, Funding, Valuation, Revenue ... - CB Insights
See NatImmune funding rounds, investors, investments, exits and more. Evaluate their financials based on NatImmune's post-money valuation and revenue.See details»
Recombinant human mannose-binding lectin(NatImmune A/S)
RATIONALE: Recombinant human mannose-binding lectin (MBL) may be effective in preventing infection in young patients with fever and neutropenia receiving chemotherapy for blood …See details»
BAMLET(NatImmune A/S) - Drug Targets, Indications, Patents
Apr 2, 2024 · BAMLET(NatImmune A/S), Initially developed by Azanta Danmark A/S, Now, its global highest R&D status is Pending, Therapeutic Areas: Neoplasms,Urogenital Diseases.See details»
Bovine lactalbumin complex with lipid(NatImmune A/S)
Bovine lactalbumin complex with lipid (NatImmune A/S), Initially developed by Azanta Danmark A/S, Now, its global highest R&D status is Pending, Therapeutic Areas: Infectious …See details»